Physicians' Academy for Cardiovascular Education

Initiating PCSK9 mAb after ACS: When and how to start?

Listen to the podcast
10' education - Mar. 22, 2023 - Prof. Wouter Jukema, MD, PhD (Leiden, The Netherlands) and Prof. Pasquale Perrone-Filardi, MD, PhD (Naples, Italy)

Video navigation menu

  • The AT-TARGET-IT study 0:31
  • Why start early? 3:32
  • Prolonged benefit of lower LDL-c 6:13
  • Adherence and persistence  7:17

In ACS patients who need additional lipid-lowering therapy, do you initiate a PCSK9 inhibitor during their hospital stay?

  • Yes, always
  • Sometimes, it varies per patient
  • No, I wait until follow-up
  • No, I prescribe another agent


Show transcript

Educational information

This video is part of a serie of expert discussions titled "Innovating science and practice - Broadening the understanding of PCSK9 mAb".


Prof. J. Wouter Jukema, MD, PhD is Professor of Cardiology at the Leiden University Medical Center in Leiden, The Netherlands.

Prof. Pasquale Perrone-Filardi, MD, PhD - Department of Clinical Medicine, Cardiovascular and Immunology Sciences, Federico II University, Naples, Italy.


This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.


Funding for this educational program was provided by an unrestricted educational grant received from Sanofi.

Find the publication of AT-TARGET-IT online at Atherosclerosis

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: